@mike98572986 Avatar @mike98572986 mike

mike posts on X about $clpt, $qure, this is, ceo the most. They currently have [-----] followers and [---] posts still getting attention that total [-----] engagements in the last [--] hours.

Engagements: [-----] #

Engagements Line Chart

Mentions: [--] #

Mentions Line Chart

Followers: [-----] #

Followers Line Chart

CreatorRank: [-------] #

CreatorRank Line Chart

Social Influence

Social category influence finance 8.26% countries 3.67% social networks 3.67% technology brands 3.67% stocks 3.67% travel destinations 0.92%

Social topic influence $clpt #2, $qure #3, this is 11.93%, ceo 8.26%, rgx 121 #1, in the 7.34%, $rgnx 6.42%, gene 6.42%, to the 5.5%, the first 5.5%

Top accounts mentioned or mentioned by @9_invest_obey @desertdweller93 @biggercapital @profdollar @petermantas @luckypenguin10 @chrisbagmancap @fiercebiotech @itsbiancamichellevideo7597966496400198967 @biotechautist @asamimes @brianskorney @leerinkpartners @clearstreetnews @marketplunger1 @beachstreetgrp @neurosurgeryosu @osugenetherapy @russelllonser @ohiostatemed

Top assets mentioned uniQure N.V. (QURE) Candel Therapeutics, Inc. (CADL)

Top Social Posts

Top posts by engagements in the last [--] hours

"$clpt decent probability clearpoint is involved here. Not called out directly. Non-viral vasculogenic reprogramming restores cognition and mitigates pathology in Alzheimers disease Ohio State program Specifically stereotactic placement of an infusion cannula into the lateral ventricle allows for precise delivery of this cell therapy. This approach mirrors existing infusion paradigms currently employed for drug administration to the intraventricular system. To assess therapeutic potential EFF-primed fibroblasts were injected into a mouse model of AD (3xTg-AD) and wild-type controls via the"
X Link 2026-01-25T17:00Z [----] followers, [----] engagements

"$clpt Neurona nothing really new mentioned the infusion takes about a hour the procedure a couple of hours. The Alzheimer's program would likely use the same drug and procedure. Phase [--] is scheduled to start mid of this year. One of the questions was about DEI lol. This is how people think in California. Epilepsy is an equal opportunity disease. https://twitter.com/i/web/status/2016971924249923822 https://twitter.com/i/web/status/2016971924249923822"
X Link 2026-01-29T20:29Z [----] followers, [----] engagements

"Minute 12:20 $qure $clpt here was the interview that we couldnt get to work from a couple weeks ago Can working up a sweat in a sauna improve your health Liam Gray and a patient that is part of the amt-130 trial and his experience. This study has shown it is possible to slow down the disease. It was a very very tightly matched population. It is a therapy that can be scaled up. Working on same day procedure in and out same day. The patient doesnt even like blood tests and was willing to do it. Jane Davis who was caring for the patient said once the results were released her workload increased"
X Link 2026-02-04T06:50Z [----] followers, [----] engagements

"Thursday Bluerocks program presentation 9:30 est if anyone is available would love to hear if anything interesting was said I will likely will not be able to attend either. $clpt Friday elad Levy [--] est might be the more interesting one. They do a lot with clearpoint https://x.com/bernardbendokmd/status/2019245645782216965s=46&t=4McZ7301H76n6S_RDt-dTw https://www.spark-bih.de/news-events/article/spark-bih-national-gct-webinar-dr-stefan-frank https://x.com/bernardbendokmd/status/2019245645782216965s=46&t=4McZ7301H76n6S_RDt-dTw"
X Link 2026-02-05T06:00Z [----] followers, [---] engagements

"$qure $clpt @DesertDweller93 Hear about AMT-130 #ClinicalTrial at #Virtual #HIPE We are pleased to have uniQure - Dr. Venugopa PharmD joining us to discuss current #HDResearch Register for Feb 21st #Help4HDHIPE2026 #UnmaskingtheTruth #HD Click here: https://t.co/oF1oE5X9sv https://t.co/rhDenpxIGO Hear about AMT-130 #ClinicalTrial at #Virtual #HIPE We are pleased to have uniQure - Dr. Venugopa PharmD joining us to discuss current #HDResearch Register for Feb 21st #Help4HDHIPE2026 #UnmaskingtheTruth #HD Click here: https://t.co/oF1oE5X9sv https://t.co/rhDenpxIGO"
X Link 2026-02-08T20:43Z [----] followers, [----] engagements

"$clpt Kenai At least [--] patients dosed so far https://empoweredpatientradio.com/stem-cell-therapy-aims-to-rebuild-brain-circuits-in-parkinsons-patients-with-dr-howard-federoff-kenai-therapeutics https://empoweredpatientradio.com/stem-cell-therapy-aims-to-rebuild-brain-circuits-in-parkinsons-patients-with-dr-howard-federoff-kenai-therapeutics"
X Link 2026-02-12T00:15Z [----] followers, [---] engagements

"$clpt $rgnx RGX-121 "I am highly encouraged by the 12-month pivotal data and continued safety and efficacy profile of RGX-121" said Roberto Giugliani M.D. Ph.D. ProfessorDepartment of Genetics UFRGS Medical Genetics Service HCPAPorto Alegre Brazil."The vast majority of Hunter syndrome patients have no current treatment options to address the neurodevelopmental decline of this disease and are in urgent need of new therapies and a one-time treatment option like RGX-121 could make a meaningful impact on their lives.""
X Link 2025-09-05T15:00Z [----] followers, [----] engagements

"$clpt program new paper Can-3110 The luck continues with clearpoint The serial samples showed that over time the drug changed the environment inside and around the tumor even though the tumor appeared to be progressing on magnetic resonance imaging (MRI) scans. This may happen because the immune system causes swelling and inflammation which can look like new or enlarging areas of contrast on a scan even when a tumor hasnt grown a phenomenon known as pseudoprogression. If CAN-3110 therapy can reshape the microenvironment and activate the immune system it may improve patient outcomes according"
X Link 2025-10-08T23:26Z [----] followers, [----] engagements

"A solid find $clpt if not following @Chrisbagmancap highly recommend Basically a $CLPT commercial Not even Day [--] yet. https://t.co/4kCJu9EXVL Basically a $CLPT commercial Not even Day [--] yet. https://t.co/4kCJu9EXVL"
X Link 2025-10-09T19:47Z [----] followers, [----] engagements

"$xpel Market is still sleeping on Xpel these guys dont care whether we are in a crap car market or a roaring car market they will continue to push forward and gain market share with new products partnerships and territories. Pape is a CEO that you can count on to do the right thing very few companies that you can completely trust leadership this is one of them. https://m.youtube.com/watchv=Ssw4bl9AqK8 https://m.youtube.com/watchv=Ssw4bl9AqK8"
X Link 2025-10-18T15:04Z [----] followers, [----] engagements

"$clpt ceo of IRRAS USA Will Martin post on LinkedIn Today is an exciting day for all of our IRRAS USA Inc. team members as we announce our company's acquisition by ClearPoint Neuro Inc. As we spent time with the ClearPoint Neuro Inc. team over recent months the strategic fit between the two companies became increasingly clear to me - the drive to bring innovation to those devastated by brain injury stroke or rare disease the passion to help patients and the drive to disrupt the status quo by enabling targeted drug delivery to the brain. Thank you to the employees and investors of IRRAS USA"
X Link 2025-11-08T05:28Z [----] followers, [----] engagements

"$clpt $cadl Can-3110 investor day comments But actually we should not forget that there's another very exciting investigational medicine which is CAN3110 which we test in probably the most difficult to treat form of cancer which is recurrent high-grade glioma. Most of these patients will have recurrent glioblastoma. So I welcome Francesca Barone Henry Brem and Kemp Dolliver. And I'm going to ask Francesca our Chief Scientific Officer to take us through some of the key data. Thank you Paul Peter. So there is a significant unmet clinical need and also a great opportunity to develop a medicine"
X Link 2025-12-06T07:12Z [----] followers, [----] engagements

"$clpt big time right here A Study of ASP2246 for People Who Have Movement Problems Caused by Brain Injury After a Stroke Astellas Pharma Inc Intracerebral parenchymal infusion via SmartFlow Neuro cannula. Procedure: Brain surgery Stereotactic brain surgery Study start 2026-02-09 [--] for enrollment @peter_mantas @biggercapital https://www.clinicaltrials.gov/study/NCT07318714 https://www.clinicaltrials.gov/study/NCT07318714"
X Link 2026-01-08T02:51Z [----] followers, [----] engagements

"@biggercapital Yeah Astellas is no joke they likely saw clearpoints work on AviadoBio and were impressed with what they saw. This is definitely a big program and big partner to have"
X Link 2026-01-08T03:34Z [----] followers, [----] engagements

"$clpt $rgnx if Rgx [---] gets approved I do wonder if RGX-111 starts getting back into action. New article just hit on a child that was part of Rgx-111. This is part of James Wilsons programs once you get [--] approved it makes all the other programs in a really good spot since they are basically using the same processes. 'He's a little miracle' East Tennessee family raises awareness on the importance of clinical trials Jerrik Johnson was diagnosed with Hurler's syndrome when he was six days old. His parents credit early diagnosis and a clinical trial to his success today. Jerrick was the third of"
X Link 2026-01-12T04:17Z [----] followers, [----] engagements

"$clpt $rgnx ceo of regenxbio speaking on rgx [---] As I mentioned for the Hunter program we're in the middle of a BLA review now. So I won't speak to a lot of specifics about that but it's a very active review. Hunter I don't think there has been a new treatment in Hunter for [--] years. And so there's a huge unmet need here. We deliver directly to the CNS. And there's roughly [---] patients in the prevalent market per se for the U.S. And on an incident basis it's ultrarare so it's roughly [--] new patients per year. There's been a lot of advance in newborn screening for MPS and we want to come in"
X Link 2026-01-15T00:30Z [----] followers, [----] engagements

"$stpt $qure $clpt Good example on why fda needs to really value the doctors patients and parents real world evidence is a powerful thing. The doctors and parents were shouting from the rooftops that the drug works. Certain fda members were extremely skeptical and willing to pull the plug on ELEVIDYS they should eat a humble piece of pie today and realize they arent always correct. Dont own $Srpt but facts are facts that drug works exactly what parents and doctors were saying. At the end of the day you see enough things you have never seen before that isnt randomness at times you need to get"
X Link 2026-01-26T15:28Z [----] followers, [----] engagements

"$clpt siren Siren believes this marks the first FDA-cleared IND for an adeno-associated virus (AAV)-based therapy in an oncology indication underscoring the growing potential of gene therapy approaches in cancer. This IND clearance represents a defining moment for Siren as we transition from a preclinical-stage company into the clinic said Nicole K. Paulk PhD Founder CEO and President of Siren Biotechnology. Reaching this milestone reflects years of focused platform development rigorous translational work and close engagement with regulators and it positions us to begin evaluating our"
X Link 2026-01-28T18:00Z [----] followers, [---] engagements

"$clpt definitely a set back we shall see how it plays out Today we announced a regulatory update on our ultra rare MPS programs. Learn more: https://t.co/bIbEjq6zIf https://t.co/TXaTl6Djnh Today we announced a regulatory update on our ultra rare MPS programs. Learn more: https://t.co/bIbEjq6zIf https://t.co/TXaTl6Djnh"
X Link 2026-01-28T18:05Z [----] followers, [----] engagements

"$clpt $rgnx Paul Schmidt on LinkedIn Yesterday FDA froze two Regenxbio gene therapy programs after finding a brain tumor in one child. Here's what the press release doesn't sayand what rare disease families are thinking right now: : One 5-year-old. Treated [--] years ago. Asymptomatic tumor found on routine MRI. Causality undetermined. Meanwhile: [--] other patients on that same therapy. Clean. [--] patients on the sister therapy. Clean. Some dosed nearly [--] years ago. Both programs frozen. Including one that was [--] days from a potential FDA decision. : Hunter syndrome doesn't wait for"
X Link 2026-01-30T04:33Z [----] followers, [----] engagements

"$qure $clpt a good time to bring awareness to the disease Will Forte Gets Candid About His Family's Health Journey with Huntington's Disease https://youtu.be/7BWWM5jjzjs https://youtu.be/7BWWM5jjzjs"
X Link 2026-01-31T21:03Z [----] followers, [----] engagements

"The grand challenge he said is getting to the point where our AI models can design a variety of molecules with very specific properties almost like tailor-made medicine for a specific person and disease. Isomorphic is now a key player in an increasingly competitive race to revolutionise drug development with AI. Were developing these new technologies that have huge promise but in the end we need to make sure that these medicines are safe he said. Nothing will be gained by racing through and then putting something on the market that isnt going to help patients. He remains committed to finding"
X Link 2026-02-01T17:45Z [----] followers, [---] engagements

"$clpt #ClearPoint Neuro is starting [----] strong with a team of over [---] people focused entirely on Neuro. Were excited to keep this momentum going and see what we can achieve together #CLPT https://t.co/twlk9jf0CP #ClearPoint Neuro is starting [----] strong with a team of over [---] people focused entirely on Neuro. Were excited to keep this momentum going and see what we can achieve together #CLPT https://t.co/twlk9jf0CP"
X Link 2026-02-02T22:20Z [----] followers, [----] engagements

"$par very good write up Posting my thoughts on $PAR AI risk as well as recent scuttlebutt https://t.co/TUYOidQOfT Posting my thoughts on $PAR AI risk as well as recent scuttlebutt https://t.co/TUYOidQOfT"
X Link 2026-02-03T01:21Z [----] followers, [----] engagements

"$par added again I guess all software is going to zero -)"
X Link 2026-02-03T18:44Z [----] followers, [----] engagements

"$clpt Kaleida Health (KH) operates three main facilities in Erie County: Bualo General MedicalCenter/Gates Vascular Institute Millard Fillmore Suburban Hospital and John R. Oishei Childrens Hospital. To meet the needs of the community KH has established a weight management clinic at BGMC for adults and established an Eating Disorder Intensive Outpatient Program for children. Kaleida also oers youth suicide prevention services through connecting youth to mental health care. Additionally Kaleida operates a blood disorder clinic in collaboration with Roswell Park Comprehensive Cancer Center and"
X Link 2026-02-03T18:56Z [----] followers, [---] engagements

"$clpt The House has passed the bill to extend the rare pediatric disease priority review voucher program to [----]. The bill is now on the Presidents desk to be signed into Law. Amazing news for patients and the industry. https://t.co/5OYsg0wJzI The House has passed the bill to extend the rare pediatric disease priority review voucher program to [----]. The bill is now on the Presidents desk to be signed into Law. Amazing news for patients and the industry. https://t.co/5OYsg0wJzI"
X Link 2026-02-03T21:24Z [----] followers, [----] engagements

"$clpt Astellas abstract of pre-clinical work for the new stroke program asp2246 The median Cyno.mRS scores for the control low-dose and high-dose ASP2246 groups were [--] [--] and [--] respectively with significant improvement noted in the high-dose group compared to the saline control (p0.05). No ASP2246-related abnormalities were observed in clinical signs food consumption or body weight during the study period. Conclusions: ASP2246 a novel mRNA-LNP drug was able to convert astrocytes into neurons in a cell culture model and improved motor dysfunction in a chronic ischemic stroke cynomolgus monkey"
X Link 2026-02-04T04:33Z [----] followers, [----] engagements

"I wouldnt go all in they are in a good position but a lot can go wrong. Just like a lot can also go right. My largest position but I believe so far the biggest risk is something coming out that is better and easier to deliver to the brain. There is definitely stuff out there working on this. I even actually expect it good news is that this industry moves extremely slow and by the time a different delivery method becomes mainstream clearpoint already had some big drugs in commercial. Not to mention clearpoint is on the frontlines so hopefully they continue to innovate and be where the puck is"
X Link 2026-02-08T16:23Z [----] followers, [---] engagements

"RT @FierceBiotech: After facing a delay and clinical hold Regenxbios Hunter syndrome gene therapy has been rejected by the FDA. Fierce in"
X Link 2026-02-10T03:35Z [----] followers, [--] engagements

"$clpt Neurona cirm presentation Anyone that hasnt been following the Neurona program very closely should listen to the presentation from a couple days ago if you have followed my account with all the Neurona updates probably not worth it but if not its a good presentation. https://youtu.be/om5_wIBBG3s https://youtu.be/om5_wIBBG3s"
X Link 2026-02-04T15:06Z [----] followers, [----] engagements

"$qure $clpt FDA document 2/2 Rare Disease Innovation Hub Goals Goal 1: Further Advance Regulatory Science of Rare Disease Therapies Create and enhance opportunities for consideration of novel endpoints biomarker development and assays innovative trial design real world evidence and statistical methods. Initiate engagement with federal research partners and the broader rare disease research community with the purpose of sharing scientific innovations and enhancing collaboration in regulatory science. https://www.fda.gov/media/185144/downloadattachment"
X Link 2026-02-04T15:19Z [----] followers, [----] engagements

"$clpt Russell Lonser interview 17:53 talks about gene therapy and real time delivery about the [--] minute mark is where I would stop. Its a new paradigm We are now thinking about how do we scale this technology and techniques https://m.youtube.com/watchv=tVfNVlOBeXM&feature=youtu.be https://m.youtube.com/watchv=tVfNVlOBeXM&feature=youtu.be"
X Link 2026-02-04T20:48Z [----] followers, [----] engagements

"$clpt Kenai If the brain can once again produce normal levels of dopamine Parkinsonsdiseasemaybe sloweddownandmotor functionrestoredsaidBrian LeeMDPhDaneurosurgeon with Keck Medicineandprincipalinvestigator of the study. We believe thattheseiPSCscanreliablymature into dopamine-producing braincellsandoffer the best chance of jump-starting the brainsdopamineproduction saidXenos Mason MD a neurologist who specializes inParkinsons disease and othermovement disorders with Keck Medicine and co-principal investigator of the study."
X Link 2026-02-06T01:12Z [----] followers, [----] engagements

"$clpt Irraflow TDC-FIT introduced in June [----] for recurrent or high-risk cSDH combined standard TDC with continuous pressure-controlled urokinase irrigation via a dual-lumen IRRAflow catheter or two single-lumen catheters connected to LiquoGuard [--]. This allowed regulated infusion and drainage to promote fibrinolysis while preventing pressure shifts. The introduction of TDC-FIT in [----] was accompanied by a rapid uptake with this technique representing 3.9% of cases in its first year and increasing to 12.6% in [----] TDC-FIT introduced in June [----] was performed in [--] cases (4.4%) mostly for"
X Link 2026-02-07T04:23Z [----] followers, [---] engagements

"$qure $clpt Looking forward to this session with Dr. Sung UAB #HD Clinic Director & prominent Principal Investigator in current #clinicaltrials Find out what #HDResearch looks like moving into [----] #Help4HDHIPE2026 #UnmaskingtheTruth Register: https://t.co/oF1oE5XHi3 https://t.co/aSv798vLUk Looking forward to this session with Dr. Sung UAB #HD Clinic Director & prominent Principal Investigator in current #clinicaltrials Find out what #HDResearch looks like moving into [----] #Help4HDHIPE2026 #UnmaskingtheTruth Register: https://t.co/oF1oE5XHi3 https://t.co/aSv798vLUk"
X Link 2026-02-08T03:23Z [----] followers, [----] engagements

"Very cool article 25-40% of clinical trial costs come from an excessive quality-check process that the FDA itself has recommended against for over a decade. Great piece from a former FDA official on why the whole system is stuck in a "too big to fail" loop. https://t.co/yX4gNVy04k https://t.co/sjbdVhioMF 25-40% of clinical trial costs come from an excessive quality-check process that the FDA itself has recommended against for over a decade. Great piece from a former FDA official on why the whole system is stuck in a "too big to fail" loop. https://t.co/yX4gNVy04k https://t.co/sjbdVhioMF"
X Link 2026-02-08T16:00Z [----] followers, [---] engagements

"$clpt this article is not about clearpoint but gives you an idea why clearpoint keeps winning a outsized amount of deals when it comes to trying to deliver to the brain. This industry doesnt mess around they like reliability and stuff that has worked. Its not worth the risk to try to get all fancy and just use some random start up for your delivery method. Joe said it best at the Mesa [----] when companies start looking for a company to use to deliver to the brain we are in a pretty unique position the fda knows our cannulas very well when getting your trial set up the fda takes about [--] months"
X Link 2026-02-08T16:39Z [----] followers, [----] engagements

"$clpt $sldb ceo call today Can you just walk us through- Yeah . strategy there I will tell you I should be I should be more excited about Duchenne than I am FA but truthfully my heart is in FA. I think this is going to be an AveXis-like moment in FA. That's my personal belief. We're gonna have to wait and see how things play out. We believe fundamentally you got to get to the dentate nucleus of the cerebellum. Of course the spinal column is important the heart is important and all of three of those areas you know become in difference of importance or different weight of importance as you age"
X Link 2026-02-13T01:06Z [----] followers, [----] engagements

"Three patients and then I'll probably read out second half of the year on the first [--] but we'll continue to dose cohort two. We call it cohort two. So we'll dose cohort one cohort two but cohort one will probably read out the second half of the year. And if it's anything great I think this is a very unique little company"
X Link 2026-02-13T01:06Z [----] followers, [---] engagements

"$clpt aadc Spanish translation special stuff Miracles of Science The daughter of a town in Barcelona has an ultra-rare disease known as childhood Parkinsons that affects only [---] children worldwide. Science is advancing and at times being born again becomes almost a reality. This is the case of Irai a girl from Barcelona who came into the world with a rare disease known as childhood Parkinsons. She couldnt speak couldnt walk and couldnt even hold up her head. She was like a rag doll and could only open and close her eyes her mother recalls on Sense Ficci on 3Cat. Today she runs talks and has"
X Link 2026-02-13T01:44Z [----] followers, [----] engagements

"$clpt Clearpoint Neuro $Qure [--] part post a novel I wrote a post a few weeks ago about why Clearpoint is having so much success on their gene therapy programs. This post will explain that at a deeper level with real evidence. I believe a lot of investors understand Clearpoint at a high level but sometimes I feel the real insights are in the weeds. It is a long post but I believe out of any key insight this is the one that tells the story. I believe this is well worth your time if interested in Clearpoint. We are going to step back in time here. The game was completely different in the past"
X Link 2025-06-29T12:14Z [----] followers, 29.5K engagements

"$clpt siren LinkedIn post by Benjamin McLeod If you're not aware of Siren Biotechnology and their CEO Nicole Paulk you're missing out on one of the most inspirational stories in gene therapy. Here's the timeline: 2017: She joins UCSF as Assistant Professor starts her own lab. Over the next couple years her team validates a bold hypothesis - targeted gene therapies delivering cytokines can absolutely demolish hard-to-treat cancer tumors. Late 2020: Nicole presents internal data to colleagues. They tell her to start a company. Fall 2021: Founds Siren Biotechnology in stealth raises seed funding"
X Link 2026-01-31T01:00Z [----] followers, [----] engagements

"$clpt Trogenix getting called out in the UK parliament Fayes teams spin-out company Trogenix has secured [--] million of new finance to expand upscale and develop. That sounds like a lot of money but I understand that [--] million is just a drop in the ocean if real progress is to be made. They are doing fantastic work. Pre-clinical studies have shown that the biotech companys breakthrough Odysseus platform could kill cancerous brain cells and stimulate the immune system against the tumours while leaving the surrounding healthy cells and tissues untouched. This massive investment will accelerate"
X Link 2026-02-14T00:54Z [----] followers, [---] engagements

"$Dcth presentation today didnt see the whole presentation things I heard 4-6 procedures per month for Dr padia [--] procedures so far in about 28-29 patients. First procedure he did was April [--] [--]. Says he is booked for February and March his backlog isnt insane anymore due to more and more centers opening on the West Coast. Seemed to imply they definitely could do more than 4-6 per month but at the end of the day they need room time and that is about what works best for the center right now. Sites are openly rapidly quote https://twitter.com/i/web/status/2022730174039839091"
X Link 2026-02-14T17:50Z [----] followers, [----] engagements

"$qure $clpt Check this out https://t.co/fhd8kV7bDj. Some pretty strong language just in time for patient access to innovative rare disease medicines. Let us see how MM & VP talk the talk but all bad actions Check this out https://t.co/fhd8kV7bDj. Some pretty strong language just in time for patient access to innovative rare disease medicines. Let us see how MM & VP talk the talk but all bad actions"
X Link 2026-02-16T05:56Z [----] followers, [----] engagements

"$clpt Just listened to the call again felt better about it tbh after hearing the call this time. The main thing I think I missed on the first call was the Biologics and drug delivery team really couldnt do much in the quarter because all their time was on the move to the new facility getting everything set up and making sure the certifications were up and running. They definitely have a lot going on mergers arent easy so that definitely has some more execution risk now. The wording on bidding for the new studies was in the [--] million + range compared to largest historically of [--] million. A"
X Link 2025-11-08T20:46Z [----] followers, [----] engagements

"$clpt some additional thoughts we can all read the scientific papers of the product they just bought and give our best estimates on what they just got but think of Clearpoints historical playbook. First [--] of the reasons clearpoint made the acquisition Second the design of the indwelling and flexible IRRAflow catheter provides ClearPoint Neuro with a launching point for the design of a longer duration infusion cannula that may open up additional biopharma partners especially in the oncology space who often require a device that allows multiple infusions over an extended duration potentially in"
X Link 2025-11-09T18:04Z [----] followers, [----] engagements

"$clpt rgx [---] $rgnx conference today Got it. So in the last few minutes I want to touch on the Hunter Syndrome program. The FDA requested some additional information. Where are you in that process right now And do you think that's going to be a major amendment Already has been. So we were asked in our mid-cycle meeting sort of in August timeframe of last year to provide we had provided six-month data on the patients for neurocog development. And by the time we had completed the rolling VLA I think FDA looked at the dosing dates and knew we would have one year's worth of data. So we supplied"
X Link 2025-11-10T23:32Z [----] followers, [----] engagements

"$clpt rgx [---] $rgnx conference yesterday transcript This is going to be the first gene therapy for Hunter's disease and it's in a market that is completely served by enzyme replacement therapy. Even though there is an enzyme replacement therapy that's presumably in development that could cross the blood brain barrier you have the potential to potentially go in there and disrupt it. Though Denali is sitting at a $3 billion valuation you guys are sitting around a $500 million-$600 million valuation. I guess how should we think about this disconnect number one. And number two how do you think"
X Link 2025-11-12T11:31Z [----] followers, [----] engagements

"$clpt $qure Tuesday November 18th Zoom meeting That is a lot of experts and KOLs speaking EHDN Platform Meeting in collaboration with HDYO and EHA on uniQure topline results: Unpacking the outcomes so far Since the release of uniQures topline results from the AMT-130 gene therapy trial followed by further updates in recent weeks there has been widespread interest across the Huntingtons disease community. This EHDN Platform Meeting organised in collaboration with HDYO and EHA will bring together leading experts and advocates to unpack what the results tell us so far and what they may mean for"
X Link 2025-11-15T00:04Z [----] followers, [----] engagements

"$clpt minute [--] same delivery on all programs AS first patient dosed last week. If Rgx [---] gets approved in February makes all these programs a lot more attractive from there https://m.youtube.com/watchv=C3SFUDfDbR4 https://m.youtube.com/watchv=C3SFUDfDbR4"
X Link 2025-11-18T00:25Z [----] followers, [----] engagements

"$clpt Average turnover is [--] minutes UBNS Check out the video pretty cool stuff The future is here This guy is a big fan of clearpoint These guys obviously use other products than clearpoint but shows where neurosurgery is going. Panelists also touched on the transformative role that philanthropy has played in accelerating the adoption of new technologies fueling our communitys professionals and making Buffalo competitive with other major research centers across the nation. Dr. Levy highlighted ClearPoint Neuro a precise minimally invasive laser therapy and navigation system that Kaleida"
X Link 2025-11-28T05:01Z [----] followers, [----] engagements

"$xpel I missed that Alta Fox bought a big position in Xpel they have been in and out on the name over the years but last 13f basically had a tracking position on and now [---] percent of the company. https://d18rn0p25nwr6d.cloudfront.net/CIK-0001767258/0cc296c0-ef4b-43a0-ae31-21cfce95a459.pdf https://d18rn0p25nwr6d.cloudfront.net/CIK-0001767258/0cc296c0-ef4b-43a0-ae31-21cfce95a459.pdf"
X Link 2025-12-09T07:59Z [----] followers, [---] engagements

"Not really true for all you know amt-130 position could change any day decision on rgx [---] in February (not a game changer but if approved that is [--] drugs past the fda possible BTD for Neurona these are all possible catalysts. The biggest one obviously is Amt-130 if you dont believe a positive conclusion will happen on that I can agree with the statement to a large degree. https://twitter.com/i/web/status/1999875103379837042 https://twitter.com/i/web/status/1999875103379837042"
X Link 2025-12-13T16:12Z [----] followers, [---] engagements

"If RGX-121 receives approval on February [--] it acts as a "green light" for the entire platform that James Wilson is working on. Especially with the fda specifically calling out platform drugs and the advantages of using pretty much the same exact processes and procedures other than the actual drug. https://twitter.com/i/web/status/2010573518967292025 https://twitter.com/i/web/status/2010573518967292025"
X Link 2026-01-12T04:44Z [----] followers, [---] engagements

"UTSW first in Texas to offer novel treatment for rare eye cancer that spreads to the liver $dcth Dr. Chandrasekarans practice focuses on treating patients with uveal melanoma melanoma and other skin cancers. Having the ability to offer Hepzato to our patients is so important. Treating this deadly disease is about creating opportunity the opportunity for patients to have access to a wide scope of options including systemic therapies clinical trials and liver-directed treatments said Dr. Chandrasekaran whohas received institutional fundingto grow the uveal melanoma programat UTSouthwestern."
X Link 2026-01-16T23:40Z [----] followers, [---] engagements

"This one will be good because all of James Wilsons projects are using the same exact formula as rgx [---]. So if it gets approved all those other programs instantly become more valuable. He has been talking about the platform solution for quite awhile. All that really changes is the drug for that specific disease they are going after. He feels if one gets approved it validates the other programs because they can use a lot of the prior work with the fda. https://twitter.com/i/web/status/2013400687523016944 https://twitter.com/i/web/status/2013400687523016944"
X Link 2026-01-19T23:58Z [----] followers, [---] engagements

"$clpt new Clearpoint partner and trial Pretty wild stuff treatment for the wealthy Furthermore Clonell has introduced a new paradigm called the Patient-Initiated Clinical Trial to overcome the limitations of traditional pharmaceutical company-led clinical trials which require enormous costs and time. This is an innovative partnership model where the patient who urgently requires treatment becomes the initiator of the clinical trial funding the commencement of their own treatment while Clonell provides patient-specific therapeutics with its unrivaled technology. In this process Clonell"
X Link 2026-01-21T23:56Z [----] followers, [----] engagements

"$clpt full disclosure no indication clearpoint is involved in this study why I find it interesting Sanofi did a May [----] Arsa study using clearpoint so definitely could be using them for the delivery to the brain part of it. The paper doesnt reference who they are using it is also interesting because it shows the current FA trials strategy from solid biosciences is definitely the right one. Some interesting things in the paper. Will reference both papers at the bottom. Icm delivery benefits - In our current systemic administration study we observed high VG distribution in the liver and heart"
X Link 2026-01-24T16:47Z [----] followers, [---] engagements

"$dcth Arizona first case Take it for what you will a couple people in the comments mentioned their hospitals are getting it soon https://www.tiktok.com/@its.biancamichelle/video/7597966496400198967 https://www.tiktok.com/@its.biancamichelle/video/7597966496400198967"
X Link 2026-01-24T20:28Z [----] followers, [----] engagements

"$par held my nose and averaged down today personally I dont like that the ceo was just running around saying he wouldnt use equity not really a fan of someone saying something and instantly doing something different but I cant sit here and say the business is struggling. From a business perspective Im comfortable with how par has been run. I will trust that they felt the asset was worth it. https://twitter.com/i/web/status/2016214983433191433 https://twitter.com/i/web/status/2016214983433191433"
X Link 2026-01-27T18:21Z [----] followers, [----] engagements

"@BiotechAutist @asamimes @BrianSkorney @LeerinkPartners @ClearStreetNews Its an interesting one because technically the first extension was due to the fda not the company your guess is good as mine what happens but obviously its not getting approved on Feb 8th"
X Link 2026-01-29T22:18Z [----] followers, [---] engagements

"Interesting https://cowboystatedaily.com/2026/01/28/wyoming-lawmaker-pushes-stem-cell-freedom-act-challenging-fda/ https://cowboystatedaily.com/2026/01/28/wyoming-lawmaker-pushes-stem-cell-freedom-act-challenging-fda/"
X Link 2026-01-30T02:57Z [----] followers, [---] engagements

"They are a bit behind Neurona with their epilepsy program but nonetheless if it truly does work it is very impressive because this program doesnt use immunosuppression which is very unique and would be a strong selling point on the program. Historically most of these programs require at least a year which some patients have issues going through that. So yes if you had multiple patients have success it would be impressive still extremely early on this program though. https://twitter.com/i/web/status/2017671174969561443 https://twitter.com/i/web/status/2017671174969561443"
X Link 2026-01-31T18:47Z [----] followers, [---] engagements

"$clpt $qure I think Peter Mantas mentioned this but I dont think it is fully appreciated enough with Clearpoint if you really start looking at all the programs together as a whole look at the numbers from early on in the trials compared to the longer they go on"
X Link 2025-06-01T03:18Z [----] followers, 14.8K engagements

"$rgnx $clpt Neurodegenerative Disease: Clemidsogene lanparvovec (RGX-121) is a potential first-in-class treatment for MPS II also known as Hunter syndrome being developed and potentially commercialized in partnership with Nippon Shinyaku. In May [----] the U.S. Food and Drug Administration (FDA) granted priority review of the BLA seeking accelerated approval for clemidsogene lanparvovec for MPS II; Prescription Drug User Fee Act (PDUFA) target action date of November [--] [----]. The FDA BLA review is progressing as planned; mid-cycle meeting and PLI and BIMO inspections were successfully completed."
X Link 2025-08-07T11:16Z [----] followers, [----] engagements

"Think $clpt has a high probability of being involved here The trial is a [--] part combo drug one part of the delivery is to the brain with CED. DB107 has received Fast Track Designation and Breakthrough Therapy Designation from the FDA as well as Orphan Drug Designations from the FDA and EMA The main guy on this is Nicholas Butowski from ucsf he has lots of prior experience with real time mri ced cannula we got [--] locations on the trial all clearpoint centers. UCSF is a huge partner of clearpoint. We got the krystof bankiewicz and alastair martin connection this recent paper wasnt on this trial"
X Link 2025-08-10T00:46Z [----] followers, [----] engagements

"$clpt Neurona-45 minutes in- Justin Graves speaks about his experience after getting the procedure My life is almost completely back to normal. Was having [--] seizures a month before the procedure. Now it is down to maybe [--] or [--]. Says he can drive and travel again. He is about to start swimming again. https://youtu.be/bhzsU9tMhvYsi=qbJu1xdRKoRC8Aau https://youtu.be/bhzsU9tMhvYsi=qbJu1xdRKoRC8Aau"
X Link 2025-09-17T01:32Z [----] followers, [----] engagements

"$clpt Askbio Gene therapy brings new hope for those suffering from heart failure Parkinson's we believe that in the beginning of the next decade there is going to be like a tsunami of innovation he said. Vanhove said the potential impact of gene therapy is significant. Of the [----] known genetic disorders about [--] percent still have no treatment. Rare diseases individually are rare but collectively we are talking about [---] million people. The unmet medical need is really high he said. He added that gene therapies using AAV have already shown durable effects lasting up to [--] years in other"
X Link 2025-09-21T15:44Z [----] followers, 11.1K engagements

"$clpt $qure When Tabrizi speaks like this who is a conservative person you better stand up and listen It means the decline you would normally expect in one year would take four years after treatment giving patients decades of "good quality life" Prof Sarah Tabrizi told BBC News. No wonder Dr. Sung was acting the way he was acting at the last speaking engagement he was dying to share good news"
X Link 2025-09-24T12:15Z [----] followers, [----] engagements

"$clpt $qure Sarah Tabriz is a like a little girl tasting ice cream for the first time on the call. She is straight up giddy never heard her talk like this. She is straight up super bullish she is all in"
X Link 2025-09-24T13:06Z [----] followers, [----] engagements

"$clpt $qure The game changer of all game changers has arrived likely [--] drugs approved for clearpoint by September of next year. The world is waking up today and this Huntingtons news is going to spread all around the globe like wildfire every single person that has a family member with HD is now going to get tested. Hold on for dear life day [--] has truly just begun. Good luck to all out there as I said earlier violence is officially here"
X Link 2025-09-24T14:00Z [----] followers, [----] engagements

"$clpt $qure More comments from Sarah Tabrizi We now have a treatment for one of the worlds more terrible diseases. This is absolutely huge. Im really overjoyed. With treatment people would be able to work and live independently for significantly longer Tabrizi said and the dramatic impact of the therapy raises the possibility that it could prevent symptoms occurring if given at an earlier stage. Now I think many more people will come forward for the genetic test because theres a treatment said Tabrizi."
X Link 2025-09-24T19:09Z [----] followers, [----] engagements

"$clpt $qure Dr Wild said the patients who took part in the trial were now stable "in a way I'm not used to seeing in Huntington's disease". Professor Stout said that if the treatment is approved by regulators in Australia it could eventually help people with Huntington's have less severe symptoms. "The kind of approach that we take in different forms of dementia is not so much looking for a cure but if we could slow the disease down enough people can live out their natural life span with a high quality of life" she said. "That's like a cure from the point of view from dementia. "The trick"
X Link 2025-09-25T00:43Z [----] followers, [----] engagements

"$clpt $qure The Sung has spoken Victor Sung a principal investigator for the trial and a movement disorders neurologist at the University of Alabama at Birmingham who is on the steering committee for uniQure said that last year interim data released on the trial was encouraging but open to critiques. An additional year of follow-up he said has surpassed expectations. He previously thought a [--] percent slowdown in progression would be impressive. Weve been burned so many times in the past with failures so everyone is always skeptical about things Sung said. The new data in his view are some of"
X Link 2025-09-25T02:05Z [----] followers, [----] engagements

"$clpt Think about the incoming inquiries clearpoint is having right now for hospitals asking to get their products so they can also get ready in the future to be able to do this procedure the sales funnel just became a true lay up"
X Link 2025-09-25T14:11Z [----] followers, [----] engagements

"$clpt $qure Brand new interview from Dr wild about amt [---] he is beyond pumped up. Must listen interview its a good one. Too many things to list off here. The affect from year 2-3 not only is it not wearing off the affect is growing and getting better. Dr wild- I speak for myself and everyone else I have spoken with [--] percent is more than anything we could have dreamed or wished for He cannot believe he is actually saying that this is the real deal this is the first treatment for Huntingtons disease like living in a dream. He cannot believe it."
X Link 2025-09-26T00:04Z [----] followers, [----] engagements

"$clpt $qure It will be necessary to work on the best ways to make this surgery faster she says. We are already working on this challenge. One patient is a former information technology professional who had to stop work due to his symptoms. About a year after being given the gene therapy he was able to go back to work Wild says. In his [--] years of research Wild says this is the only patient hes seen who could do that. But others who expected to be in a wheelchair by now are still walking. https://www.sciencenews.org/article/huntingtons-slowed-with-gene-therapy"
X Link 2025-09-27T00:47Z [----] followers, [----] engagements

"$clpt $qure Good thoughts about procedure from Courtney Rice from Acadia Strategy Partners on LinkedIn regarding amt-130 A few thoughts on uniQures fabulous news in Huntingtons disease from yesterday Ive seen speculation around how complex administration for this drug might be. WHERE: Will complexity limit administration to a tiny group of COEsIn the US the Phase I/II took place in [--] centers.Analysts have noted that the skill to place this therapy falls well within the skill set of a board-certified neurosurgeon. Recall deep brain stimulation for Parkinsons requires similar invasiveness so"
X Link 2025-09-27T02:19Z [----] followers, [----] engagements

"Been getting a lot of dms this week about clearpoint $clpt if you want to know what you need to know this thread is all still true on why things are happening now. I dont know where stock goes near term but this is the crux of the big picture and the main things that an investor fully needs to grasp if they are going to hold long term. $clpt Clearpoint Neuro $Qure [--] part post a novel I wrote a post a few weeks ago about why Clearpoint is having so much success on their gene therapy programs. This post will explain that at a deeper level with real evidence. I believe a lot of investors"
X Link 2025-09-27T03:39Z [----] followers, [----] engagements

"Recommend Peter is one of the top guys out there easily when it comes to Clearpoint knowledge $clpt Did a podcast with @marketplunger1 post $QURE data to talk about what it means for $QURE and $CLPT. Enjoy Did a podcast with @marketplunger1 post $QURE data to talk about what it means for $QURE and $CLPT. Enjoy"
X Link 2025-09-27T15:32Z [----] followers, 11.3K engagements

"$clpt New clearpoint study dont have access to full article but Here we review the experience of a single surgeon with interventional MRI guided DBS targeting of the VIM in ET patients under general anesthesia in a community setting. Method: We conducted a retrospective chart review of ET patients who underwent DBS under general anesthesia using an MRI-guided ClearPoint surgical technique at Willis-Knighton Health System between [----] and [----] Results: A total of [---] ET patients underwent placement of [---] DBS leads. The 2D Radial Error on the was [----] [----] mm with only [--] leads requiring more"
X Link 2025-09-27T19:36Z [----] followers, [----] engagements

"$qure $clpt Statement from Katie Jackson ceo of help for HD this community is going to rally around this drug like you have never seen before wouldnt surprise me if FDA actually speeds this one up Katie Jackson CEO of Help [--] HD was asked her initial response to the news today. We wanted to share that response with our community. Katie Jackson: I wanted to share my initial thoughts and feelings and I must admit they may surprise you. I have been an advocate for Huntington's disease for almost [--] years. I vividly remember going to Costco to buy the biggest bag of flash-frozen blueberries I"
X Link 2025-09-27T20:01Z [----] followers, 17.6K engagements

"$clpt Askbio new presentation on ab [----] for Parkinsons minute [----] about delivery. We realized why GDNF hasnt worked it was due to delivery in the last 20-30 years it was the delivery techniques that were the problem not the gene therapy. That was the problem in all the prior studies. We feel our new strategy is a more effective way to get it to the brain. 9:40 mri guided using a system called Clearpoint this is less invasive than DBS some surgeons say the hole is so small they dont even need to close it. Dont have to shave your head. Only a 2-3 hour procedure. Shows videos of the cannula in"
X Link 2025-09-27T21:14Z [----] followers, [----] engagements

"$clpt $qure Mum died of Huntingtons. this breakthrough changes everything In a call to investors uniQure estimated the cost would be similar to other gene therapies which can be more than $2m a patient. Wild thinks this would be justifiable. Gene therapies are expensive but treating peoples symptoms and looking after people with HD is very expensive Wild said. Delaying the disease in an 18-year-old so symptoms arrive when they are [---] rather than [--] justifies the expense he added. Sheahan had decided never to get tested unless I was thinking of having children or getting married she said. But"
X Link 2025-09-28T15:14Z [----] followers, [----] engagements

"$clpt With the recent hire of Paul Larson if Im clearpoint I would hire about 5-7 of the top people in this field that have worked with them for a very long time. I would give them RSUs and get them on board. Im not going to list the [--] but my next hire is Krystof Bankiewicz and Mark Richardson these type of people provide massive long term value. Not only do they continually bring Clearpoint big partnerships but they also allow Clearpoint to be on the cutting edge on what is going on in the field. They should lock them down pay them the value is hard to measure on [--] year timeframes but it is"
X Link 2025-09-28T17:09Z [----] followers, [----] engagements

"$clpt $qure Some new quotes Wild explained that when the gene that causes Huntingtons (HTT) was first discovered in [----] the technology didnt exist to selectively reduce production of disease-causing programs and a range of therapeutic techniques needed to be developed over time. Wild added: To keep things in perspectiveit could have taken [--] years longer without ever seeing a success like this. In the current trial patients had mild signs or symptoms of the disease. But the disease process is essentially the same from birth to death so lowering the protein before symptoms begin should delay"
X Link 2025-09-29T16:24Z [----] followers, [----] engagements

"$clpt Candel Therapeutics Q4 readout not expecting anything here [----] percent of cancer trials fail Additional clinical and biomarker activity data from an ongoing phase 1b clinical trial evaluating repeat doses of CAN-3110 in patients with recurrent high-grade glioma (rHGG) is expected in Q4 [----]. Im more bullish on some of their other cancer programs. Saw this posted on figshare https://figshare.com/articles/figure/MRI_Images/28950887 https://figshare.com/articles/figure/MRI_Images/28950887"
X Link 2025-09-30T22:19Z [----] followers, [---] engagements

"$clpt Bluerock Neurona possibly some real catalysts upcoming Shout out to @BeachStreetGrp for reminding me that Bluerock might post the [--] months results in the prior trial they posted [--] months late September [----]. They are under no obligation to do so we shall see if they do. This would be on the prior trial and not phase [--]. Neurona usually posts an update in December. That could be a very good one. This would be on the prior trial and not the phase [--]. A lot of amt-130 news in the upcoming months. Q4 readout for Can-3110 not expecting anything here but it is a read out. Rgx [---] by Feb 2026"
X Link 2025-10-01T07:10Z [----] followers, [----] engagements

"$clpt $qure More comments from Victor Sung I cried with every single patient Sung says. It just was this crazy feeling that for the patients and families almost cant feel real. Weve had so many failures and theres been a lot of heartbreak over many years in this community Sung says. So to have something that at least really appears to be having an impact is really significant. This is a community that has been waiting for so long for some kind of breakthrough says Rachel Harding a toxicologist at the University of Toronto who helps develop therapies that target the cause of Huntingtons"
X Link 2025-10-01T17:27Z [----] followers, 12.6K engagements

"$clpt This is really smart and makes more sense on what Joe was talking about on the last call. Our partners are telling us they would like all the procedures to be the same the same workflow and products. With this it allows that to be more of a possible reality not to mention this gives them a good chance of speeding up the time of the procedures which is extremely important in a future world where you will run up on capacity constraint situations if multiple gene therapies get approved over time."
X Link 2025-10-01T21:44Z [----] followers, [----] engagements

"$clpt CEO of Bluerock doing a presentation in [--] days https://www.linkedin.com/posts/sethettenberg_cgmesa25-activity-7379501053668458496-5_GL https://www.linkedin.com/posts/sethettenberg_cgmesa25-activity-7379501053668458496-5_GL"
X Link 2025-10-03T15:40Z [----] followers, [----] engagements

"$clpt You also have to remember clearpoint will be getting paid by the commercial partner they arent going to need to wait for insurance to pay out. If a commercial partner also decides to make long term deals with insurance companies to cover more procedures and get paid out over years that will not be happening with clearpoint you would get the full payment of the procedure. Im not saying amt-130 will need or have a performance type of pay out with insurance companies but it is something to think about with other products down the road"
X Link 2025-10-04T18:51Z [----] followers, [----] engagements

"$clpt this is very good news Were delighted to share that Chair of @NeurosurgeryOSU and Director of @OSUGeneTherapy Russell Lonser M.D. (@RussellLonser) has been named President-Elect of the American Academy of Neurological Surgery (#AAcNS). #Neurosurgery @OhioStateMed @OSUWexMed @OSUCCC_James https://t.co/cx8p46d3re Were delighted to share that Chair of @NeurosurgeryOSU and Director of @OSUGeneTherapy Russell Lonser M.D. (@RussellLonser) has been named President-Elect of the American Academy of Neurological Surgery (#AAcNS). #Neurosurgery @OhioStateMed @OSUWexMed @OSUCCC_James"
X Link 2025-11-06T13:47Z [----] followers, [----] engagements

"$clpt upcoming stuff Trash quarter [--] sites activated need to pick up that pace. Possible reversal on the decision for amt-130 the next couple of months is going to have a lot of discussion on this one. Dec 5-9 Neurona will release new data Acquisition expected to close in q4 Rgx 121- decision by Feb 8th Guiding to 54-60 million for [--] if acquisition closes before [--] starts. I believe that is a sandbagging guide but if I was Joe it is the type of guide I am making today until closure and end of q4. [--] is the year where they need to execute no real excuses to not have a really strong year"
X Link 2025-11-07T01:40Z [----] followers, 22.2K engagements

"$par looks like Adam Wyden sold the heck out of par either is seeing something concerning or wanted to be more diversified"
X Link 2025-11-14T22:27Z [----] followers, [----] engagements

"$clpt $cadl Jefferies [----] Healthcare Conference The last few minutes I want to spend to talk about CAN-3110. This is a different mechanism of action. It's also a viral immunotherapy but it's a true oncolytic virus. It's replication competent HSV. Unlike everybody else that has deleted the so-called ICP34.5 gene so think of Imlygic think of Replimune programs and others everybody has knocked out the [----] gene. Why Because it is associated with neurotoxicity. That makes a lot of sense. However if you do that you create a virus that's less effective. What we've done is we have inserted one copy"
X Link 2025-11-19T05:22Z [----] followers, [----] engagements

"$par Erbert & Gerberts Transforms Operations with PARs Unified Restaurant Platform New POS payments delivery loss recovery and menu management solutions streamline complexity and boost efficiency across [--] locations https://partech.com/wp-content/uploads/2025/11/112025-par-Erbert-Gerberts-Release-Final.pdf https://partech.com/wp-content/uploads/2025/11/112025-par-Erbert-Gerberts-Release-Final.pdf"
X Link 2025-11-20T15:39Z [----] followers, [---] engagements

"Par wins $par Catalyst has been right in the open Papa Johns Partners with PAR Technology to Power POS and OPS Transformation Across [----] U.S. Restaurants A full system rollout is planned across all U.S. corporate and franchise locations by the end of [----]. https://www.businesswire.com/news/home/20260112168759/en/Papa-Johns-Partners-with-PAR-Technology-to-Power-POS-and-OPS-Transformation-Across-3200-U.S.-Restaurants https://www.businesswire.com/news/home/20260112168759/en/Papa-Johns-Partners-with-PAR-Technology-to-Power-POS-and-OPS-Transformation-Across-3200-U.S.-Restaurants"
X Link 2026-01-12T21:14Z [----] followers, [----] engagements

"$clpt Irraflow The main studies to keep an eye on NCT05118997 NCT05970549 NCT06649097 NCT05649904 https://clinicaltrials.gov/study/NCT05649904term=Irraflow&rank=3 https://clinicaltrials.gov/study/NCT06649097term=Irraflow&rank=1 https://clinicaltrials.gov/study/NCT05970549term=Irraflow&rank=4 https://clinicaltrials.gov/study/NCT05118997term=Irraflow&rank=2 https://clinicaltrials.gov/study/NCT05649904term=Irraflow&rank=3 https://clinicaltrials.gov/study/NCT06649097term=Irraflow&rank=1 https://clinicaltrials.gov/study/NCT05970549term=Irraflow&rank=4"
X Link 2026-01-25T18:39Z [----] followers, [---] engagements

"$clpt irraflow experience https://info.irras.com/case-spotlight-dr.-s.-joy-trybula https://info.irras.com/case-spotlight-dr.-s.-joy-trybula"
X Link 2026-01-25T20:02Z [----] followers, [---] engagements

"$clpt Latus bio That shift was articulated most starkly by Ghoroghchian. A physician-scientist and serial founder he described a capital market that has fundamentally reset expectations for advanced modality companies. The bar has become incredibly high he said explaining that early clinical programs must now demonstrate not just safety but meaningful signals of efficacy to attract sustained investment. At Latus Bio that reality has driven a relentless focus on efficiency. To raise a Series B today you have to have enough capital in your Series A to get to a meaningful clinical endpoint"
X Link 2026-01-26T03:18Z [----] followers, [---] engagements

"$clpt AVB-101 The entire procedure lasts about ten hours explains Dr. Vincenzo Levi Functional Neurosurgeon and Sub-Investigator of the ASPIRE-FTD clinical trial. The injection requires an extremely high level of precision but the real novelty lies in the ability to see and assess in real time how the drug spreads within the selected brain area. The thalamus is a structure that is well interconnected with the frontal and temporal lobes which are affected by the disease and thanks to its deep connections with the cerebral cortex it allows the drug to spread over the widest possible area Levi"
X Link 2026-01-27T03:14Z [----] followers, [----] engagements

"$qure $clpt #letstalkabouthd and how you can ask your Members of Congress to urge the FDA to allow AMT-130 to move forward to a science-driven review with HDSA New Jersey Chapter Vice-President Karl Miran. #HuntingtonsDisease #HD #HDSA #AMT130 #FDA #Advocacy https://t.co/drcd8MRf3l #letstalkabouthd and how you can ask your Members of Congress to urge the FDA to allow AMT-130 to move forward to a science-driven review with HDSA New Jersey Chapter Vice-President Karl Miran. #HuntingtonsDisease #HD #HDSA #AMT130 #FDA #Advocacy https://t.co/drcd8MRf3l"
X Link 2026-01-27T23:20Z [----] followers, [----] engagements

"$clpt Neurona Join CIRM's Closer to Cures speaker series Jan [--] 10:30 AM (PST). Hear from Dr. Cory Nicholas (Neurona Therapeutics) & Dr. Crystal Mackall (@Stanford) on #Epilepsy & #BrainCancer clinical trials. Public invited to attend board meeting. https://t.co/YVfBp3a7d4 #ClinicalTrials https://t.co/O5P1Xec9v0 Join CIRM's Closer to Cures speaker series Jan [--] 10:30 AM (PST). Hear from Dr. Cory Nicholas (Neurona Therapeutics) & Dr. Crystal Mackall (@Stanford) on #Epilepsy & #BrainCancer clinical trials. Public invited to attend board meeting. https://t.co/YVfBp3a7d4 #ClinicalTrials"
X Link 2026-01-27T23:20Z [----] followers, [----] engagements

"$clpt Bluerock She also describes it as groundbreaking and says people with Parkinsons in Australia will be able to have new baby brain cells inserted via a surgical procedure. This method looks at modifying the disease itself rather than just treating the symptoms says Professor Carolyn Sue (the studys lead investigator) Associate Professor Lehn (helping recruit patients and develop trial ethics) says: I dont want to give people false hope but its something that is super exciting. We dont have any therapy so no surgery no medicine that stops or slows down the underlying Parkinsons disease."
X Link 2026-01-28T17:47Z [----] followers, [----] engagements

"$clpt litt for the military I would assume this is for litt in general. Policy change opens access to minimally invasive neurosurgery for more than nine millionin the U.S. armed forces and their families https://www.prnewswire.com/news-releases/monteris-medical-leads-effort-to-secure-tricare-coverage-for-laser-interstitial-thermal-therapy-litt-for-military-members-302672738.html https://www.prnewswire.com/news-releases/monteris-medical-leads-effort-to-secure-tricare-coverage-for-laser-interstitial-thermal-therapy-litt-for-military-members-302672738.html"
X Link 2026-01-29T00:05Z [----] followers, [---] engagements

Limited data mode. Full metrics available with subscription: lunarcrush.com/pricing